Cargando…

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper

SIMPLE SUMMARY: Proton pump inhibitors are frequently used in cancer patients to alleviate some symptoms, epigastric pain or heartburn. However, acid suppression decreases the absorption of some oral-targeted anticancer treatments (tyrosine kinase inhibitors, CDK4/6 inhibitors) and induces changes i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raoul, Jean-Luc, Edeline, Julien, Simmet, Victor, Moreau-Bachelard, Camille, Gilabert, Marine, Frénel, Jean-Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909698/ https://www.ncbi.nlm.nih.gov/pubmed/35267464 http://dx.doi.org/10.3390/cancers14051156

Ejemplares similares

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer
por: Raoul, Jean-Luc, et al.
Publicado: (2021)

Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
por: Raoul, J.L., et al.
Publicado: (2023)

Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis
por: Moreau-Bachelard, Camille, et al.
Publicado: (2022)

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2019)

How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma
por: Raoul, Jean-Luc, et al.
Publicado: (2016)

Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients
por: Moreau-Bachelard, Camille, et al.
Publicado: (2020)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
por: Gilabert, Marine, et al.
Publicado: (2018)

Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer Centers
por: Bocquet, François, et al.
Publicado: (2023)

How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective
por: Raoul, Jean-Luc, et al.
Publicado: (2014)

New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations
por: Edeline, Julien, et al.
Publicado: (2022)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper
por: Cholley, Bernard, et al.
Publicado: (2019)

Perioperative hemodynamic optimization: from guidelines to implementation—an experts’ opinion paper
por: Fellahi, Jean-Luc, et al.
Publicado: (2021)

Proton pump inhibitors reduce the accuracy of faecal immunochemical test for detecting advanced colorectal neoplasia in symptomatic patients
por: Rodriguez-Alonso, Lorena, et al.
Publicado: (2018)

Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema
por: Rahal, Soraya, et al.
Publicado: (2014)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

IgE-mediated allergy to proton pump inhibitors with both delayed and immediate onset
por: Barakat, Leyla, et al.
Publicado: (2019)

Bazex Syndrome Revealing a Gastric Cancer
por: Robert, Maxime, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Use and overuse of proton pump inhibitors
por: Staiano, Annamaria, et al.
Publicado: (2015)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors
por: Janett, Simone, et al.
Publicado: (2015)

Hypomagnesaemia associated with long-term use of proton pump inhibitors
por: Toh, James Wei Tatt, et al.
Publicado: (2015)

Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
por: Kinoshita, Yoshikazu, et al.
Publicado: (2018)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: A retrospective analysis by the Association Française de Chirurgie
por: Gilabert, Marine, et al.
Publicado: (2017)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism
por: Swaminathan, Krishnan
Publicado: (2015)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?
por: Alsalahi, Omran, et al.
Publicado: (2015)

Proton pump inhibitors affect the gut microbiome
por: Imhann, Floris, et al.
Publicado: (2016)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

Proton Pump Inhibitor-associated Mucosal Change
por: Kato, Mototsugu, et al.
Publicado: (2017)

Proton pump inhibitors induce hemolytic anemia
por: Al-Nasser, Asayil Nasser, et al.
Publicado: (2019)

When is proton pump inhibitor use appropriate?
por: Yadlapati, Rena, et al.
Publicado: (2017)

Use of proton pump inhibitors in general practice
por: Tosetti, Cesare, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5o2g22en61j3ckvm8fh17sv98g